Consistent implementation of strategic focus continues to bear fruit with aap reporting 10% sales growth and EBITDA up by 54% in H1 2011
(Thomson Reuters ONE) -
aap Implantate AG /
Consistent implementation of strategic focus continues to bear fruit with aap
reporting 10% sales growth and EBITDA up by 54% in H1 2011
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
aap Implantate AG, a medical technology company listed in the Prime Segment of
the Frankfurt Stock Exchange, reports for the first-half of 2011 a 10% sales
increase at product level to EUR 14.1 million (previous year: EUR 12.8 million)
and an EBITDA of EUR 2.1 million (previous year: EUR 1.4 million), a 54%
increase on H1 2010.
+-----------------------+------------+------------+--------+
| In EUR million | H1/2011 | H1/2010 | Change |
+-----------------------+------------+------------+--------+
| Sales | 14.1 | 12.8 | 10% |
+-----------------------+------------+------------+--------+
| EBITDA | 2.1 | 1.4 | 54% |
+-----------------------+------------+------------+--------+
| EBIT | 0.7 | 0.03 | >100% |
+-----------------------+------------+------------+--------+
| Cash-EBIT | -0.3 | -1.0 | n. a. |
+-----------------------+------------+------------+--------+
| In EUR million | 06/30/2011 | 12/31/2010 | Change |
+-----------------------+------------+------------+--------+
| Equity (equity ratio) | 48.2 (73%) | 44.9 (70%) | 7% |
+-----------------------+------------+------------+--------+
| Balance sheet total | 65.8 | 63.6 | 3% |
+-----------------------+------------+------------+--------+
| Employees | 249 | 256 | -3% |
+-----------------------+------------+------------+--------+
The Group's EBIT was EUR 0.7 million (previous year: EUR 0.03 million). On a
balance sheet total of EUR 65.8 million (Dec. 31, 2010: EUR 63.6 million) the
equity ratio rose to 73% due in part to a second-quarter capital increase. Cash
EBIT (EBIT excluding internally produced and capitalized assets and depreciation
of them) amounted to EUR -0.3 million (previous year: EUR -1.0 million).
Following the launch of the WSG product line in the German market the Trauma
Center of Excellence in Berlin is preparing the launch in countries that
recognize the CE mark. At the same time, the company is working on the FDA
approval; applications will be submitted at the beginning of the fourth quarter
to the responsible authorities. Furthermore, a distribution agreement has been
signed with an internationally active orthopaedic enterprise, thereby ensuring
deliveries of aap`s cannulated screws to the US market. In Dieburg, the Center
of Excellence for Bone Cement and Cementing Techniques has reached an advanced
stage in negotiations with a global enterprise on the development of a bone
cement for use in joint replacement.
To further improve the Company's financial position and ensure further
profitable growth in 2011 a number of cost saving options are under
consideration. They include reducing rental costs, comparing offers made by
different service companies and harmonizing raw material suppliers across the
Group.
aap Implantate AG's full Q2 report is available for download at www.aap.de.
________________________
aap Implantate AG (ISIN DE0005066609)
- Prime Standard/Regulated Market - All German stock markets -
aap is a medical technology company that develops, manufactures and markets
biomaterials and implants for the areas Ortho/Trauma/Spine. Its product
portfolio includes bone cements, bone graft substitutes, antibiotic carriers,
and implants for fracture healing and joint replacement. In addition to its
Berlin HQ the Company has sites in Dieburg near Frankfurt am Main and Nijmegen
in the Netherlands. aap Implantate AG stock has been listed in the Prime
Standard segment of the Frankfurt Stock Exchange since May 16, 2003.
For inquiries please contact:
aap Implantate AG, Nanette Huedepohl, Head of Corporate Communications,
Lorenzweg 5, 12099 Berlin, Germany, Tel.: +49 30 7501 9133, fax:
+49 30 7501 9290, n.huedepohl(at)aap.de
For more details please visit www.aap.de
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via Thomson Reuters ONE
[HUG#1537311]
Unternehmensinformation / Kurzprofil:
Datum: 10.08.2011 - 07:55 Uhr
Sprache: Deutsch
News-ID 57094
Anzahl Zeichen: 5740
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 145 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Consistent implementation of strategic focus continues to bear fruit with aap reporting 10% sales growth and EBITDA up by 54% in H1 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
